Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Switching to Humira biosimilars saved Navitus clients more than $315 million in upfront costs in 2024 and resulted in a 60% ...

President Donald J. Trump has signaled that lowering the costs of prescription drugs will be a priority for his second term.

Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within the pharmaceutical division called ...

McKesson Corporation (NYSE:MCK) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. On June 11, analyst ...

Biosimilars marketed in the US typically have list prices 15% to 35% lower than ... sometimes force diabetics to ration their use of the drugs. Semglee's latest approval follows the publication ...

After digesting Cardinal Health's 2025 investor day, we inched up our 2026 revenue and EPS assumptions and lifted our stage II growth rates by 50 basis points to reflect a stronger distribution market ...

Amgen has priced Bkemv at a roughly 10% discount to Soliris, which has a list price ... the reference drug, meaning that pharmacists in the US will be able to substitute the biosimilar for Soliris ...

Both Johnson & JohnsonJNJ and MerckMRK are leading U.S. healthcare conglomerates — blue-chip pharmaceutical companies with ...

Medicare Advantage will see major changes starting in 2025, cutting drug costs and expanding services—key info for beneficiaries to stay prepared.